 CAMBRIDGE, Mass.--BUSINESS WIRE--- ALVR ASH20--AlloVir Nasdaq: ALVR, a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration FDA has cleared the Investigational New Drug IND application for ALVR106, an allogeneic, off-the-shelf virus-specific T cell therapy VST designed to target infections and diseases caused by respiratory syncytial virus RSV, influenza, parainfluenza virus PIV, and human metapneumovirus hMPV. The IND enables AlloVir to initiate a Ph 